A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd on the progression to type 1 diabetes in children with multiple islet cell autoantibodies

Trial Profile

A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd on the progression to type 1 diabetes in children with multiple islet cell autoantibodies

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms DiAPREV-IT; DiAPREV-IT 1
  • Most Recent Events

    • 13 Jun 2017 According to a Diamyd Medical media release, the company is now analysing mechanistic data collected over the years and planning to follow up this trial.
    • 13 Jun 2017 According to a Diamyd Medical media release, results from this trial were presented at the Diabetes Conference of the American Diabetes Associations (ADA) 77th Scientific Sessions
    • 13 Jun 2017 5-years follow up results published in the Diamyd Medical Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top